Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer

Detalhes bibliográficos
Autor(a) principal: Silva, Gabriela
Data de Publicação: 2021
Outros Autores: Sales-Dias, Joana, Casal, Diogo B., Alves, Sara, Domenici, Giacomo, Barreto, Clara, Matos, Carolina, Lemos, Ana R., Matias, Ana T., Kucheryava, Khrystyna, Ferreira, Andreia, Moita, Maria Raquel, Braga, Sofia, Brito, Catarina, Cabral, M. Guadalupe, Casalou, Cristina, Barral, Duarte C., Sousa, Pedro M. F., Videira, Paula A., Bandeiras, Tiago M., Barbas, Ana
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/147438
Resumo: Funding Information: Funding: This research was funded by Fundação para a Ciência e Tecnologia, Portugal, grants PTDC/BBB-BMD/4497/2014 (to A.B.) and PD/BD/113987/2015 (to J.S.-D.), iBETXplore grants 3D-ABC-PI-717 (to G.D.) and BiACaT-HER2:JAG1 (to G.S.). iNOVA4Health—UIDB/04462/2020 and UIDP/04462/2020, a program financially supported by Fundação para a Ciência e Tecnolo-gia/Ministério da Ciência, Tecnologia e Ensino Superior, through national funds is acknowledged. Funding from the INTERFACE Programme, through the Innovation, Technology and Circular Economy Fund (FITEC), is gratefully acknowledged. Support was also provided by the Applied Molecular Biosciences Unit—UCIBIO, which is financed by national funds from Fundação para a Ciência e Tecnologia (UIDP/04378/2020 and UIDB/04378/2020). Funding Information: This research was funded by Funda??o para a Ci?ncia e Tecnologia, Portugal, grants PTDC/BBB-BMD/4497/20141 (to A.B.) and PD/BD/113987/2015 (to J.S.-D.), iBETXplore grants 3D-ABC-PI-717 (to G.D.) and BiACaT-HER2:JAG1 (to G.S.). iNOVA4Health?UIDB/04462/2020 and UIDP/04462/2020, a program financially supported by Funda??o para a Ci?ncia e Tecnologia/Minist?rio da Ci?ncia, Tecnologia e Ensino Superior, through national funds is acknowledged. Funding from the INTERFACE Programme, through the Innovation, Technology and Circular Economy Fund (FITEC), is gratefully acknowledged. Support was also provided by the Applied Molecular Biosciences Unit?UCIBIO, which is financed by national funds from Funda??o para a Ci?ncia e Tecnologia (UIDP/04378/2020 and UIDB/04378/2020). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
id RCAP_4a1eb03561d7bd2f87e439220fac5e96
oai_identifier_str oai:run.unl.pt:10362/147438
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancerAngiogenesisCell proliferationDLL1ER breast cancerMonoclonal antibodyNotch signalingTumor growthOncologyCancer ResearchSDG 3 - Good Health and Well-beingFunding Information: Funding: This research was funded by Fundação para a Ciência e Tecnologia, Portugal, grants PTDC/BBB-BMD/4497/2014 (to A.B.) and PD/BD/113987/2015 (to J.S.-D.), iBETXplore grants 3D-ABC-PI-717 (to G.D.) and BiACaT-HER2:JAG1 (to G.S.). iNOVA4Health—UIDB/04462/2020 and UIDP/04462/2020, a program financially supported by Fundação para a Ciência e Tecnolo-gia/Ministério da Ciência, Tecnologia e Ensino Superior, through national funds is acknowledged. Funding from the INTERFACE Programme, through the Innovation, Technology and Circular Economy Fund (FITEC), is gratefully acknowledged. Support was also provided by the Applied Molecular Biosciences Unit—UCIBIO, which is financed by national funds from Fundação para a Ciência e Tecnologia (UIDP/04378/2020 and UIDB/04378/2020). Funding Information: This research was funded by Funda??o para a Ci?ncia e Tecnologia, Portugal, grants PTDC/BBB-BMD/4497/20141 (to A.B.) and PD/BD/113987/2015 (to J.S.-D.), iBETXplore grants 3D-ABC-PI-717 (to G.D.) and BiACaT-HER2:JAG1 (to G.S.). iNOVA4Health?UIDB/04462/2020 and UIDP/04462/2020, a program financially supported by Funda??o para a Ci?ncia e Tecnologia/Minist?rio da Ci?ncia, Tecnologia e Ensino Superior, through national funds is acknowledged. Funding from the INTERFACE Programme, through the Innovation, Technology and Circular Economy Fund (FITEC), is gratefully acknowledged. Support was also provided by the Applied Molecular Biosciences Unit?UCIBIO, which is financed by national funds from Funda??o para a Ci?ncia e Tecnologia (UIDP/04378/2020 and UIDB/04378/2020). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.The Notch-signaling ligand DLL1 has emerged as an important player and promising therapeutic target in breast cancer (BC). DLL1-induced Notch activation promotes tumor cell proliferation, survival, migration, angiogenesis and BC stem cell maintenance. In BC, DLL1 overexpression is associated with poor prognosis, particularly in estrogen receptor-positive (ER+) subtypes. Directed therapy in early and advanced BC has dramatically changed the natural course of ER+ BC; however, relapse is a major clinical issue, and new therapeutic strategies are needed. Here, we report the development and characterization of a novel monoclonal antibody specific to DLL1. Using phage display technology, we selected an anti-DLL1 antibody fragment, which was converted into a full human IgG1 (Dl1.72). The Dl1.72 antibody exhibited DLL1 specificity and affinity in the low nanomolar range and significantly impaired DLL1-Notch signaling and expression of Notch target genes in ER+ BC cells. Functionally, in vitro treatment with Dl1.72 reduced MCF-7 cell proliferation, migration, mammosphere formation and endothelial tube formation. In vivo, Dl1.72 significantly inhibited tumor growth, reducing both tumor cell proliferation and liver metastases in a xenograft mouse model, without apparent toxicity. These findings suggest that anti-DLL1 Dl1.72 could be an attractive agent against ER+ BC, warranting further preclinical investigation.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)Centro de Estudos de Doenças Crónicas (CEDOC)iNOVA4Health - pólo NMSInstituto de Tecnologia Química e Biológica António Xavier (ITQB)DCV - Departamento de Ciências da VidaUCIBIO - Applied Molecular Biosciences UnitRUNSilva, GabrielaSales-Dias, JoanaCasal, Diogo B.Alves, SaraDomenici, GiacomoBarreto, ClaraMatos, CarolinaLemos, Ana R.Matias, Ana T.Kucheryava, KhrystynaFerreira, AndreiaMoita, Maria RaquelBraga, SofiaBrito, CatarinaCabral, M. GuadalupeCasalou, CristinaBarral, Duarte C.Sousa, Pedro M. F.Videira, Paula A.Bandeiras, Tiago M.Barbas, Ana2023-01-12T22:16:47Z2021-08-022021-08-02T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/147438eng2072-6694PURE: 33310345https://doi.org/10.3390/cancers13164074info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-22T18:08:04Zoai:run.unl.pt:10362/147438Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-22T18:08:04Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer
title Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer
spellingShingle Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer
Silva, Gabriela
Angiogenesis
Cell proliferation
DLL1
ER breast cancer
Monoclonal antibody
Notch signaling
Tumor growth
Oncology
Cancer Research
SDG 3 - Good Health and Well-being
title_short Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer
title_full Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer
title_fullStr Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer
title_full_unstemmed Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer
title_sort Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer
author Silva, Gabriela
author_facet Silva, Gabriela
Sales-Dias, Joana
Casal, Diogo B.
Alves, Sara
Domenici, Giacomo
Barreto, Clara
Matos, Carolina
Lemos, Ana R.
Matias, Ana T.
Kucheryava, Khrystyna
Ferreira, Andreia
Moita, Maria Raquel
Braga, Sofia
Brito, Catarina
Cabral, M. Guadalupe
Casalou, Cristina
Barral, Duarte C.
Sousa, Pedro M. F.
Videira, Paula A.
Bandeiras, Tiago M.
Barbas, Ana
author_role author
author2 Sales-Dias, Joana
Casal, Diogo B.
Alves, Sara
Domenici, Giacomo
Barreto, Clara
Matos, Carolina
Lemos, Ana R.
Matias, Ana T.
Kucheryava, Khrystyna
Ferreira, Andreia
Moita, Maria Raquel
Braga, Sofia
Brito, Catarina
Cabral, M. Guadalupe
Casalou, Cristina
Barral, Duarte C.
Sousa, Pedro M. F.
Videira, Paula A.
Bandeiras, Tiago M.
Barbas, Ana
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
Centro de Estudos de Doenças Crónicas (CEDOC)
iNOVA4Health - pólo NMS
Instituto de Tecnologia Química e Biológica António Xavier (ITQB)
DCV - Departamento de Ciências da Vida
UCIBIO - Applied Molecular Biosciences Unit
RUN
dc.contributor.author.fl_str_mv Silva, Gabriela
Sales-Dias, Joana
Casal, Diogo B.
Alves, Sara
Domenici, Giacomo
Barreto, Clara
Matos, Carolina
Lemos, Ana R.
Matias, Ana T.
Kucheryava, Khrystyna
Ferreira, Andreia
Moita, Maria Raquel
Braga, Sofia
Brito, Catarina
Cabral, M. Guadalupe
Casalou, Cristina
Barral, Duarte C.
Sousa, Pedro M. F.
Videira, Paula A.
Bandeiras, Tiago M.
Barbas, Ana
dc.subject.por.fl_str_mv Angiogenesis
Cell proliferation
DLL1
ER breast cancer
Monoclonal antibody
Notch signaling
Tumor growth
Oncology
Cancer Research
SDG 3 - Good Health and Well-being
topic Angiogenesis
Cell proliferation
DLL1
ER breast cancer
Monoclonal antibody
Notch signaling
Tumor growth
Oncology
Cancer Research
SDG 3 - Good Health and Well-being
description Funding Information: Funding: This research was funded by Fundação para a Ciência e Tecnologia, Portugal, grants PTDC/BBB-BMD/4497/2014 (to A.B.) and PD/BD/113987/2015 (to J.S.-D.), iBETXplore grants 3D-ABC-PI-717 (to G.D.) and BiACaT-HER2:JAG1 (to G.S.). iNOVA4Health—UIDB/04462/2020 and UIDP/04462/2020, a program financially supported by Fundação para a Ciência e Tecnolo-gia/Ministério da Ciência, Tecnologia e Ensino Superior, through national funds is acknowledged. Funding from the INTERFACE Programme, through the Innovation, Technology and Circular Economy Fund (FITEC), is gratefully acknowledged. Support was also provided by the Applied Molecular Biosciences Unit—UCIBIO, which is financed by national funds from Fundação para a Ciência e Tecnologia (UIDP/04378/2020 and UIDB/04378/2020). Funding Information: This research was funded by Funda??o para a Ci?ncia e Tecnologia, Portugal, grants PTDC/BBB-BMD/4497/20141 (to A.B.) and PD/BD/113987/2015 (to J.S.-D.), iBETXplore grants 3D-ABC-PI-717 (to G.D.) and BiACaT-HER2:JAG1 (to G.S.). iNOVA4Health?UIDB/04462/2020 and UIDP/04462/2020, a program financially supported by Funda??o para a Ci?ncia e Tecnologia/Minist?rio da Ci?ncia, Tecnologia e Ensino Superior, through national funds is acknowledged. Funding from the INTERFACE Programme, through the Innovation, Technology and Circular Economy Fund (FITEC), is gratefully acknowledged. Support was also provided by the Applied Molecular Biosciences Unit?UCIBIO, which is financed by national funds from Funda??o para a Ci?ncia e Tecnologia (UIDP/04378/2020 and UIDB/04378/2020). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
publishDate 2021
dc.date.none.fl_str_mv 2021-08-02
2021-08-02T00:00:00Z
2023-01-12T22:16:47Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/147438
url http://hdl.handle.net/10362/147438
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2072-6694
PURE: 33310345
https://doi.org/10.3390/cancers13164074
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817545908065140736